📣 VC round data is live. Check it out!

Idorsia Valuation Multiples

Discover Idorsia's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals and more.

Idorsia Overview

About Idorsia

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.


Founded

2017

HQ

Switzerland

Employees

552

Financials (LTM)

Revenue: $284M
EBITDA: ($82M)

EV

$3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Idorsia Financials

Idorsia reported last 12-month revenue of $284M and negative EBITDA of ($82M).

In the same LTM period, Idorsia generated $254M in gross profit, ($82M) in EBITDA losses, and had net loss of ($148M).

Revenue (LTM)


Idorsia P&L

In the most recent fiscal year, Idorsia reported revenue of $281M and EBITDA of ($58M).

Idorsia is unprofitable as of last fiscal year, with gross margin of 91%, EBITDA margin of (21%), and net margin of (45%).

See analyst estimates for Idorsia
LTMLast FY202320242025202620272028
Revenue$284M$281M$194M$143M$281M
Gross Profit$254M$254M$185M$97M$254M
Gross Margin90%91%95%68%91%
EBITDA($82M)($58M)($324M)($287M)($58M)
EBITDA Margin(29%)(21%)(167%)(200%)(21%)
EBIT Margin(38%)(36%)(356%)(300%)(53%)
Net Profit($148M)($126M)($379M)($336M)($142M)
Net Margin(52%)(45%)(196%)(234%)(51%)
Net Debt-$1B---

Financial data powered by Morningstar, Inc.

Idorsia Stock Performance

Idorsia has current market cap of $1B, and enterprise value of $3B.

Market Cap Evolution


Idorsia's stock price is $5.39.

Idorsia share price decreased by 5.8% in the last 30 days, and increased by 96.7% in the last year.

Idorsia has an EPS (earnings per share) of $-0.49.

See more trading valuation data for Idorsia
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3B$1B-4.0%-5.8%21.3%96.7%$-0.49

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Idorsia Valuation Multiples

Idorsia trades at 10.3x EV/Revenue multiple, and (35.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Idorsia

EV / Revenue (LTM)


Idorsia Financial Valuation Multiples

As of June 4, 2026, Idorsia has market cap of $1B and EV of $3B.

Idorsia has a P/E ratio of (9.3x).

LTMLast FY202320242025202620272028
EV/Revenue10.3x10.5x15.1x20.5x10.5x
EV/EBITDA(35.9x)(50.7x)(9.1x)(10.2x)(50.7x)
EV/EBIT(26.9x)(29.1x)(4.2x)(6.8x)(19.8x)
EV/Gross Profit11.5x11.5x15.9x30.1x11.5x
P/E(9.3x)(10.9x)(3.6x)(4.1x)(9.7x)
EV/FCF(17.9x)(13.8x)(3.6x)(5.9x)(13.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Idorsia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Idorsia Margins & Growth Rates

Idorsia grew revenue by 3% but EBITDA decreased by 4% in the last fiscal year.

In the most recent fiscal year, Idorsia reported gross margin of 91%, EBITDA margin of (21%), and net margin of (45%).

See estimated margins and future growth rates for Idorsia

Idorsia Margins

Last FY202420252026202720282029
Gross Margin91%68%91%88%
EBITDA Margin(21%)(200%)(21%)(19%)
EBIT Margin(36%)(300%)(53%)(41%)
Net Margin(45%)(234%)(51%)(61%)
FCF Margin(76%)(345%)(76%)(13%)

Idorsia Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%(26%)96%3%
Gross Profit Growth(0%)(47%)161%(0%)
EBITDA Growth(4%)(11%)(80%)(4%)
EBIT Growth19%(38%)(65%)(19%)
Net Profit Growth41%(11%)(58%)25%
FCF Growth(83%)(39%)(57%)(83%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Idorsia Operational KPIs

Idorsia's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.7M for the same period.

Idorsia's Rule of 40 is (16%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Idorsia's Rule of X is (12%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Idorsia
LTMLast FY202320242025202620272028
Rule of 40(15%)(16%)---
Bessemer Rule of X6%(12%)---
Revenue per Employee-$0.5M---
Opex per Employee-$0.7M---
G&A Expenses to Revenue-100%249%243%100%
R&D Expenses to Revenue45%47%193%128%46%
Opex to Revenue-143%452%368%143%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Idorsia Competitors

Idorsia competitors include Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals, Sinopep, Ardelyx, Uniphar, Celltrion Pharm, ArriVent BioPharma and Septerna.

Most Idorsia public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Inhibrx Biosciences1072.6x1855.4x(11.1x)-
Precigen146.1x24.3x(12.7x)(20.8x)
Immatics15.3x17.0x(4.4x)(3.7x)
Semnur Pharmaceuticals----
Sinopep5.7x-14.9x-
Ardelyx3.3x2.9x(45.7x)(107.1x)
Uniphar0.5x0.5x11.6x11.1x
Celltrion Pharm3.9x-26.4x-

This data is available for Pro users. Sign up to see all Idorsia competitors and their valuation data.

Start Free Trial

Acquisitions by Idorsia

Idorsia has acquired 1 company to date.

Last acquisition by Idorsia was on July 23rd 2020. Idorsia acquired Vaxxilon for $2M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Idorsia

Vaxxilon
Description
-
HQ CountrySwitzerland
HQ City
Basel
Deal Date23 Jul 2020
Valuation$2M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Idorsia acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Idorsia

Idorsia has invested in 1 company to date.

Latest investment by Idorsia was on October 30th 2016. Idorsia invested in Owkin in their $2M Seed round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Idorsia

Owkin
Description
Owkin is a Paris-headquartered AI company with offices in New York and London, founded in 2016, that accelerates drug discovery and clinical trials using federated learning. It partners with Sanofi and Servier to analyze siloed biomedical data for cancer treatments, identifying drug candidates and diagnostic tools while preserving patient privacy. The company raised over $255 million, achieving unicorn status in 2021 via a $180 million Sanofi investment.
HQ CountryUnited States
HQ City
New York City, NY
Deal Date30 Oct 2016
RoundSeed
Raised$2M
InvestorsBrent Hoberman; Idorsia; Jorg Mohaupt; NJF Capital; Shana Fisher
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Idorsia investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Idorsia

When was Idorsia founded?Idorsia was founded in 2017.
Where is Idorsia headquartered?Idorsia is headquartered in Switzerland.
How many employees does Idorsia have?As of today, Idorsia has over 552 employees.
Is Idorsia publicly listed?Yes, Idorsia is a public company listed on SIX Swiss Exchange.
What is the stock symbol of Idorsia?Idorsia trades under IDIA ticker.
When did Idorsia go public?Idorsia went public in 2017.
Who are competitors of Idorsia?Idorsia main competitors include Inhibrx Biosciences, Precigen, Immatics, Semnur Pharmaceuticals, Sinopep, Ardelyx, Uniphar, Celltrion Pharm, ArriVent BioPharma, Septerna.
What is the current market cap of Idorsia?Idorsia's current market cap is $1B.
What is the current revenue of Idorsia?Idorsia's last 12 months revenue is $284M.
What is the current revenue growth of Idorsia?Idorsia revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Idorsia?Current revenue multiple of Idorsia is 10.3x.
Is Idorsia profitable?No, Idorsia is not profitable.
What is the current EBITDA of Idorsia?Idorsia has negative EBITDA and is not profitable.
What is Idorsia's EBITDA margin?Idorsia's last 12 months EBITDA margin is (29%).
What is the current EV/EBITDA multiple of Idorsia?Current EBITDA multiple of Idorsia is (35.9x).
What is the current FCF of Idorsia?Idorsia's last 12 months FCF is ($164M).
What is Idorsia's FCF margin?Idorsia's last 12 months FCF margin is (58%).
What is the current EV/FCF multiple of Idorsia?Current FCF multiple of Idorsia is (17.9x).
How many companies Idorsia has acquired to date?As of June 2026, Idorsia has acquired 1 company.
What was the largest acquisition by Idorsia?$2M acquisition of Vaxxilon on 23rd July 2020 was the largest M&A Idorsia has done to date.
What companies Idorsia acquired?Idorsia acquired Vaxxilon.
In how many companies Idorsia has invested to date?As of June 2026, Idorsia has invested in 1 company.
What was the last Idorsia investment?On 30th October 2016 Idorsia invested in Owkin, participating in a $2M Seed round, alongside Brent Hoberman, Jorg Mohaupt, NJF Capital, and Shana Fisher.
In what companies Idorsia invested in?Idorsia invested in Owkin.

See public comps similar to Idorsia

Lists including Idorsia

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial